the German NITAG publishes the background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine

Document de référence
12 Mars 2019

The STIKO recommends vaccination with the adjuvanted herpes zoster subunit (HZ/su) inactivated vaccine for the prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) for all people age 60 years and over (standard vaccination).


This recommendation takes into account the good efficacy of the vaccine, the anticipated period of protection it provides, and the increased risk of severe HZ disease and post-zoster pain in individuals age 60 years and over. Models of the epidemiological effects of vaccination show that administering the HZ/su vaccine at age 60 years has the greatest effect in preventing all HZ cases, and administering the vaccine at age 70 years showed the greatest effect in preventing PHN, in a vaccinated cohort. According to the results of a health economics model, the lowest cost per quality-adjusted life year (QALY) would be achieved with vaccination at age 65 years. The number of people who need to be vaccinated (number needed to vaccinate, NNV) to prevent one case of HZ is the same for both vaccination ages (60 and 65 years). In light of the fact that preventing HZ is the key prerequisite to preventing complications and late sequelae such as PHN, 60 years of age is considered the most favorable age for vaccination, to prevent both HZ and its complications.
The STIKO also recommends vaccination against HZ and PHN with the HZ/su inactivated vaccine for all people from the age of 50 years who have an elevated risk of HZ and PHN owing to increased health risks as a consequence of an underlying disease or immunosuppression (indication-based vaccination). This group includes e. g. people with congenital or acquired immunodeficiency or immunosuppression, HIV infection, rheumatoid arthritis, systemic lupus erythematosus, chronic inflammatory bowel disease, chronic obstructive pulmonary disease (COPD) or bronchial asthma, chronic renal disease, diabetes mellitus.
The efficacy and safety of the vaccine for patients with impaired immune systems have been demonstrated in numerous studies.
Stratified data analyses on the efficacy of the vaccine have shown no difference in comparison to overall efficacy for patients with an underlying disease, e. g., rheumatoid arthritis, chronic renal disease, COPD, or diabetes mellitus, who were enrolled in vaccine marketing authorization studies.

Actualités et évènements en relation

  • Allemagne

    Les GTCV se digitalisent!


    STIKO, le GTCV de l’Allemagne, lance son application. Une première dans la communauté des GTCVs. Que ce soit sur Android ou IOS, tout le monde peut désormais  télécharger l’application et avoir ainsi accès aux recommandations du comité. Le but? "renforcer le lien entre les praticiens et le comité d’expertise sur les vaccins" expliquent Ole Wichmann et Judith Koch, membres du secretariat du STIKO.

    Lire la suite
  • Allemagne

    Vaccination recommendations by STIKO


    The national immunization schedule is developed by STIKO, and an updated version is usually published once a year (usually in August) in the Epidemiological Bulletin of the Robert Koch Institute. STIKO has translated the vaccination recommendations endorsed during the 79th and 81st STIKO meetings and which are considered enacted upon their publication on 24 August 2015.

    Lire la suite
  • Chili

    Chile's NITAG documents the results of the committee's evaluation


    In this article, we describe the structure, functioning and work processes of Chile’s NITAG (CAVEI) and assess its functionality, quality of work processes and outputs, and integration of the committee into the Ministry of Health policy process using the Assessment tool for National Immunization Technical Advisory Groups.

    Lire la suite